Finn, Richard S. http://orcid.org/0000-0003-2494-2126
Cristofanilli, Massimo
Ettl, Johannes
Gelmon, Karen A.
Colleoni, Marco
Giorgetti, Carla
Gauthier, Eric
Liu, Yuan
Lu, Dongrui R.
Zhang, Zhe
Bartlett, Cynthia Huang
Slamon, Dennis J.
Turner, Nicholas C.
Rugo, Hope S.
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 25 March 2020
Accepted: 30 June 2020
First Online: 11 August 2020
Compliance with ethical standards
:
: RS Finn has received consulting fees from Pfizer Inc, AstraZeneca, Bayer, Novartis, Bristol-Myers Squibb, Eisai, Eli Lilly, Merck, and Roche, as well as other research funding from Pfizer Inc, and honoraria from Bayer, Pfizer Inc, Bristol-Myers Squibb, Novartis, Eisai, and Eli Lilly. M Cristofanilli has received honoraria from Pfizer Inc and has been a consultant or advisor for Dompé, Agendia, and Vortex. J Ettl has received consulting fees from Eli Lilly, Pfizer Inc, Novartis Pharma KK, Eisai, and Roche; honoraria from AstraZeneca, Pfizer Inc, Eli Lilly, Novartis Pharma KK, and Roche; and travel support from AstraZeneca, Pfizer Inc, Novartis, and Eli Lilly. KA Gelmon has received consulting/advisory fees from Pfizer Inc, Novartis, AstraZeneca, NanoString Technologies, and Merck. M Colleoni has received honoraria from Novartis and has been a consultant or advisor for Pierre Fabre, Pfizer Inc, OBI Pharma, Puma Biotechnology, Celldex, and AstraZeneca. E Gauthier, Y Liu, DR Lu, and Z Zhang are employees of and may own stock in Pfizer Inc. C Giorgetti and C Huang Bartlett are former employees of and may own stock in Pfizer Inc. DJ Slamon has received consulting fees from Pfizer Inc, Eli Lilly, and Novartis; has performed contracted research for Pfizer Inc and Novartis; is a Pfizer Inc stockholder; has received travel accommodation/expenses from Pfizer Inc and BioMarin; and has a leadership role in BioMarin. NC Turner has received honoraria from Pfizer Inc, has been a consultant or advisor for Pfizer Inc, and has received research funding from Pfizer Inc, Eli Lilly, and Novartis. HS Rugo’s institution received research funding from Plexxikon, Macrogenetics, OBI Pharma, Eisai, Pfizer Inc, Novartis, Eli Lilly, Roche, and Merck.
: The PALOMA-2 and PALOMA-3 studies were approved by an institutional review board and/or an independent ethics committee at each participating site. All patients provided written informed consent before study enrollment. The studies were conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.
: Not applicable.